Molecular Diagnostics in Non-Small Cell Lung Carcinoma.

doi:10.1055/s-0039-3399564

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Molecular Diagnostics in Non-Small Cell Lung Carcinoma.

Seminars in respiratory and critical care medicine - 1 Jun 2020

Sholl Lynette M

Abstract excerpt

Current clinical practice guidelines recognize EGFR, BRAF, ALK, and ROS1 as essential molecular biomarkers, and a host of other genetic alterations as emerging biomarkers for non-small cell lung carcinoma patients. The available approaches to detecting relevant alterations in these genes are diverse and often complementary. Laboratories have increasingly migrated away from a "single-gene test" approach, embracing...

Topics

Anaplastic Lymphoma Kinase
Biomarkers
Carcinoma, Non-Small-Cell Lung
ErbB Receptors
Genes, Neoplasm
Genetic Testing
High-Throughput Nucleotide Sequencing
Humans
Lung Neoplasms
Mutation
Practice Guidelines as Topic
Protein-Tyrosine Kinases
Proto-Oncogene Proteins
Proto-Oncogene Proteins B-raf

Source

Open in PubMed

Identifiers

PMID: 32450593
DOI: 10.1055/s-0039-3399564

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics